Eli Lilly and Company $LLY Stake Raised by N10 Assets LLC

Posted by Stanley Muller on Oct 14th, 2026

Eli Lilly and Company logo N10 Assets LLC raised its stake in shares of Eli Lilly and Company (NYSE:LLY – Free Report) by 14.9% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 4,676 shares of the company’s stock after acquiring an additional 606 shares during the period. Eli Lilly and Company makes up 2.0% of N10 Assets LLC’s holdings, making the stock its 19th biggest holding. N10 Assets LLC’s holdings in Eli Lilly and Company were worth $5,411,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also made changes to their positions in LLY. Generate Investment Management Ltd raised its position in Eli Lilly and Company by 8.4% in the third quarter. Generate Investment Management Ltd now owns 57,065 shares of the company’s stock valued at $66,029,000 after purchasing an additional 4,409 shares during the period. WestHill Financial Advisors Inc. purchased a new position in shares of Eli Lilly and Company during the third quarter worth $485,000. MinichMacGregor Wealth Management LLC boosted its position in shares of Eli Lilly and Company by 19.8% during the third quarter. MinichMacGregor Wealth Management LLC now owns 968 shares of the company’s stock worth $1,120,000 after buying an additional 160 shares during the period. First Citizens Bank & Trust Co. boosted its position in shares of Eli Lilly and Company by 22.3% during the third quarter. First Citizens Bank & Trust Co. now owns 38,512 shares of the company’s stock worth $44,561,000 after buying an additional 7,019 shares during the period. Finally, Focus Financial Network Inc. grew its stake in shares of Eli Lilly and Company by 9.0% in the third quarter. Focus Financial Network Inc. now owns 7,646 shares of the company’s stock valued at $8,847,000 after buying an additional 632 shares in the last quarter. 82.53% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on LLY shares. Sanford C. Bernstein boosted their price objective on Eli Lilly and Company from $1,300.00 to $1,385.00 and gave the company an “outperform” rating in a report on Tuesday, July 14th. Truist Financial increased their target price on Eli Lilly and Company from $1,370.00 to $1,376.00 and gave the stock a “buy” rating in a research note on Friday, August 7th. JPMorgan Chase & Co. raised their target price on Eli Lilly and Company from $1,400.00 to $1,500.00 and gave the company an “overweight” rating in a report on Monday, September 28th. Morgan Stanley raised their target price on Eli Lilly and Company from $1,419.00 to $1,430.00 and gave the company an “overweight” rating in a report on Wednesday, October 7th. Finally, Berenberg Bank set a $1,400.00 target price on Eli Lilly and Company and gave the company a “buy” rating in a research report on Tuesday, September 15th. One analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $1,313.43.

Check Out Our Latest Stock Report on LLY

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

Positive Sentiment: Analysts are increasingly focused on retatrutide, Lilly’s next-generation obesity treatment, which could become a larger growth driver than Zepbound if clinical results and regulatory progress remain favorable. Investors may view the drug as helping extend Lilly’s leadership in the fast-growing cardiometabolic market. Eli Lilly Reports Earnings on Oct. 29. Here’s Why the Retatrutide Story Matters More Than the Quarter
Positive Sentiment: Erste Group Bank modestly raised its FY2026 and FY2027 earnings-per-share estimates to $36.55 and $47.30, respectively. The upward revisions reinforce expectations for continued earnings momentum, with the FY2026 estimate also above the broader consensus cited in the report. Eli Lilly earnings estimate revisions
Positive Sentiment: Lilly reported progress in a Phase 1 food-effect study of tersolisib (LY406480), providing another incremental update from its development pipeline. The study is early stage, but continued clinical activity can support confidence that Lilly is building growth opportunities beyond its current blockbuster medicines. Lilly’s Tersolisib Food-Effect Study Marks Quiet But Important Pipeline Progress
Positive Sentiment: Lilly’s collaboration with Prelude Therapeutics will evaluate the experimental KAT6A degrader PRT13722 in combination with breast-cancer therapies, with Phase 1 enrollment expected to begin in the fourth quarter of 2026. The partnership expands Lilly’s oncology pipeline, though commercial impact is distant. Prelude Announces Clinical Trial Collaboration and Supply Agreement with Lilly
Neutral Sentiment: Investors are preparing for Lilly’s October 29 quarterly report, with analysts expecting continued earnings growth. The results, guidance and management commentary on Zepbound, retatrutide and manufacturing capacity could be more important than the quarter’s headline numbers. Eli Lilly and Company Earnings Preview: What to Expect
Negative Sentiment: A study of a drug combination that produced greater weight loss than Zepbound also showed substantially higher discontinuation rates, highlighting tolerability and adherence risks for future obesity treatments. Lilly’s premium valuation leaves the stock sensitive to disappointing clinical or earnings news. Drug combination generated more weight loss but higher discontinuation rates

Insider Buying and Selling at Eli Lilly and Company

In other news, EVP Anat Hakim sold 5,000 shares of the business’s stock in a transaction dated Friday, August 7th. The stock was sold at an average price of $1,190.00, for a total transaction of $5,950,000.00. Following the completion of the transaction, the executive vice president directly owned 11,875 shares of the company’s stock, valued at approximately $14,131,250. The trade was a 29.63% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Donald A. Zakrowski sold 2,000 shares of the company’s stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $1,185.01, for a total transaction of $2,370,020.00. Following the sale, the chief accounting officer owned 1,526 shares in the company, valued at $1,808,325.26. The trade was a 56.72% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 13,500 shares of company stock valued at $15,958,170 in the last quarter. Corporate insiders own 0.14% of the company’s stock.

Eli Lilly and Company Stock Up 3.9%

Shares of NYSE:LLY traded up $45.27 during trading on Wednesday, hitting $1,211.78. The company’s stock had a trading volume of 1,446,274 shares, compared to its average volume of 2,944,073. The business has a 50 day moving average price of $1,176.60 and a two-hundred day moving average price of $1,102.08. The company has a market capitalization of $1.14 trillion, a PE ratio of 40.67, a P/E/G ratio of 1.52 and a beta of 0.46. The company has a debt-to-equity ratio of 1.41, a quick ratio of 1.00 and a current ratio of 1.35. Eli Lilly and Company has a fifty-two week low of $783.85 and a fifty-two week high of $1,292.65.

Eli Lilly and Company (NYSE:LLY – Get Free Report) last announced its quarterly earnings data on Wednesday, August 5th. The company reported $8.38 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.40 by $1.98. The business had revenue of $22.97 billion for the quarter, compared to analysts’ expectations of $20.82 billion. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%. The company’s revenue for the quarter was up 47.7% compared to the same quarter last year. During the same period last year, the firm earned $6.31 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. As a group, research analysts expect that Eli Lilly and Company will post 34.79 EPS for the current fiscal year.

Eli Lilly and Company Profile

(Free Report)

Eli Lilly and Company is a global pharmaceutical company headquartered in Indianapolis, Indiana. Founded in 1876 by Colonel Eli Lilly, the company researches, develops, manufactures and markets medicines for a range of conditions, including diabetes, obesity, cancer, immunological disorders, neurological diseases and pain.

Its products include Mounjaro and Zepbound, which contain tirzepatide and are used for type 2 diabetes and chronic weight management, respectively. Other key medicines include Trulicity for diabetes, Verzenio for certain breast cancers, Taltz for inflammatory and autoimmune conditions, Humalog insulin, and Kisunla for early symptomatic Alzheimer’s disease.